Triptorelin: Comprehensive Research Overview
Document Version: 1.0 Last Updated: December 2024 Classification: Research Paper - GnRH Agonist Therapeutics
1. Executive Summary
Triptorelin is a decapeptide (pGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂) and potent GnRH agonist used for androgen deprivation therapy in prostate cancer and treatment of central precocious puberty. The key D-tryptophan substitution at position 6 increases potency 13-fold for LH release and provides resistance to degradation.
Mechanism: Paradoxical Suppression
Initial GnRH agonism causes gonadotropin surge, followed by receptor downregulation and sustained suppression:
- Week 1-2: LH/FSH surge → temporary testosterone increase
- Week 3-4: Pituitary desensitization → chemical castration
- Maintenance: Testosterone <20 ng/dL (stricter than surgical castration threshold)
Clinical Applications
FDA-Approved:
- Advanced prostate cancer (Trelstar: 3.75 mg/month, 11.25 mg/3-month, 22.5 mg/6-month depot)
- Central precocious puberty (Triptodur: 22.5 mg/6-month IM)
Molecular Formula: C₆₄H₈₂N₁₈O₁₃ Molecular Weight: 1,311.46 Da
Safety: Cardiovascular events, bone loss, hot flashes, decreased libido; requires ongoing monitoring
Regulatory Status: FDA-approved; first-line treatment for hormone-responsive prostate cancer
Document Prepared By: Research Team, Epiq Aminos